Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Drops By 81.7%

Hypera S.A. (OTCMKTS:HYPMY) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 3,000 shares, a drop of 81.7% from the June 30th total of 16,400 shares. Based on an average daily volume of 35,600 shares, the short-interest ratio is currently 0.1 days.

Hypera Price Performance

OTCMKTS:HYPMY traded up $0.39 during trading hours on Friday, hitting $5.36. 855 shares of the company were exchanged, compared to its average volume of 14,245. Hypera has a 52-week low of $4.94 and a 52-week high of $9.43. The stock has a market capitalization of $3.40 billion, a price-to-earnings ratio of 9.04 and a beta of 1.03. The company’s 50 day moving average price is $5.34 and its 200-day moving average price is $6.04.

Hypera (OTCMKTS:HYPMY) last released its earnings results on Friday, April 26th. The company reported $0.12 earnings per share (EPS) for the quarter. The firm had revenue of $368.97 million during the quarter.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.